Oxford BioDynamics (LON:OBD) Reaches New 52-Week Low – Should You Sell?

Oxford BioDynamics Plc (LON:OBD)’s share price reached a new 52-week low on Wednesday . The stock traded as low as GBX 0.45 ($0.01) and last traded at GBX 0.47 ($0.01), with a volume of 2391988 shares. The stock had previously closed at GBX 0.50 ($0.01).

Oxford BioDynamics Stock Performance

The company has a quick ratio of 2.80, a current ratio of 0.68 and a debt-to-equity ratio of 370.22. The stock has a fifty day moving average price of GBX 0.65 and a two-hundred day moving average price of GBX 1.83. The company has a market capitalization of £8.79 million, a price-to-earnings ratio of -0.08 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last posted its quarterly earnings data on Friday, February 28th. The biotechnology company reported GBX (4.50) (($0.06)) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.